Difference between revisions of "Bicalutamide (Casodex)"
Jump to navigation
Jump to search
m |
|||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 11: | Line 11: | ||
==Patient drug information== | ==Patient drug information== | ||
*[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dfee4fe7-8478-4a3e-925d-00be3cd0ab67 Bicalutamide (Casodex) package insert]<ref name="insert"></ref> | *[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dfee4fe7-8478-4a3e-925d-00be3cd0ab67 Bicalutamide (Casodex) package insert]<ref name="insert"></ref> | ||
| − | *[https://chemocare.com/ | + | *[https://chemocare.com/druginfo/bicalutamide.aspx Bicalutamide (Casodex) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/bicalutamide.aspx Bicalutamide (Casodex) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/bicalutamide-patient-drug-information Bicalutamide (Casodex) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/bicalutamide-patient-drug-information Bicalutamide (Casodex) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/bicalutamide-patient-drug-information Bicalutamide (Casodex) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/bicalutamide-patient-drug-information Bicalutamide (Casodex) patient drug information (UpToDate)]</ref> | ||
| Line 18: | Line 18: | ||
**1997-12-12: Converted to regular approval for use in combination therapy with a luteinizing-hormone releasing hormone (LHRH) analogue for the treatment of advanced [[prostate cancer]]. ''(Based on Schellhammer et al. 1995)'' | **1997-12-12: Converted to regular approval for use in combination therapy with a luteinizing-hormone releasing hormone (LHRH) analogue for the treatment of advanced [[prostate cancer]]. ''(Based on Schellhammer et al. 1995)'' | ||
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
| − | * | + | *1995-02-28: EURD |
| + | |||
==History of changes in Health Canada indication== | ==History of changes in Health Canada indication== | ||
*1995-11-02: Initial notice of compliance for use in combination therapy with either a luteinizing hormone releasing hormone (LHRH) analogue or surgical castration in the treatment of metastatic (Stage D2) [[prostate cancer]]. | *1995-11-02: Initial notice of compliance for use in combination therapy with either a luteinizing hormone releasing hormone (LHRH) analogue or surgical castration in the treatment of metastatic (Stage D2) [[prostate cancer]]. | ||
==Also known as== | ==Also known as== | ||
| − | *'''Brand names:''' Casodex, Cosudex, Calutide, Kalumid | + | *'''Brand names:''' Bical, Bicalmid, Bicalon, Bicatero, Binarex, Casodex, Cassotide, Cosudex, Calutide, Kalumid, Procalut, Prosmide, Utamide |
==References== | ==References== | ||
Revision as of 01:40, 30 March 2024
General information
Class/mechanism: Antiandrogen; non-steroidal androgen receptor inhibitor that competitively inhibits androgens by binding to cytosol androgen receptors.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Bicalutamide (Casodex) package insert[1]
- Bicalutamide (Casodex) patient drug information (Chemocare)[3]
- Bicalutamide (Casodex) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1995-10-04: Initial accelerated approval for use in combination therapy with a luteinizing-hormone releasing hormone (LHRH) analogue for the treatment of advanced prostate cancer. (Based on Schellhammer et al. 1995)
- 1997-12-12: Converted to regular approval for use in combination therapy with a luteinizing-hormone releasing hormone (LHRH) analogue for the treatment of advanced prostate cancer. (Based on Schellhammer et al. 1995)
History of changes in EMA indication
- 1995-02-28: EURD
History of changes in Health Canada indication
- 1995-11-02: Initial notice of compliance for use in combination therapy with either a luteinizing hormone releasing hormone (LHRH) analogue or surgical castration in the treatment of metastatic (Stage D2) prostate cancer.
Also known as
- Brand names: Bical, Bicalmid, Bicalon, Bicatero, Binarex, Casodex, Cassotide, Cosudex, Calutide, Kalumid, Procalut, Prosmide, Utamide